2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation : A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Copyright © 2024. Published by Elsevier Inc..
AIM: The "2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Patients With Atrial Fibrillation" provides recommendations to guide clinicians in the treatment of patients with atrial fibrillation.
METHODS: A comprehensive literature search was conducted from May 12, 2022, to November 3, 2022, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. Additional relevant studies, published through November 2022, during the guideline writing process, were also considered by the writing committee and added to the evidence tables, where appropriate.
STRUCTURE: Atrial fibrillation is the most sustained common arrhythmia, and its incidence and prevalence are increasing in the United States and globally. Recommendations from the "2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation" and the "2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation" have been updated with new evidence to guide clinicians. In addition, new recommendations addressing atrial fibrillation and thromboembolic risk assessment, anticoagulation, left atrial appendage occlusion, atrial fibrillation catheter or surgical ablation, and risk factor modification and atrial fibrillation prevention have been developed.
| Errataetall: |
ErratumIn: J Am Coll Cardiol. 2024 Mar 5;83(9):959. - PMID 38418011 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:83 |
|---|---|
| Enthalten in: |
Journal of the American College of Cardiology - 83(2024), 1 vom: 02. Jan., Seite 109-279 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 05.01.2024 Date Revised 16.04.2024 published: Print-Electronic ErratumIn: J Am Coll Cardiol. 2024 Mar 5;83(9):959. - PMID 38418011 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jacc.2023.08.017 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365340294 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365340294 | ||
| 003 | DE-627 | ||
| 005 | 20240416232357.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jacc.2023.08.017 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1377.xml |
| 035 | |a (DE-627)NLM365340294 | ||
| 035 | |a (NLM)38043043 | ||
| 035 | |a (PII)S0735-1097(23)06465-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a Writing Committee Members |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation |b A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.01.2024 | ||
| 500 | |a Date Revised 16.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumIn: J Am Coll Cardiol. 2024 Mar 5;83(9):959. - PMID 38418011 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024. Published by Elsevier Inc. | ||
| 520 | |a AIM: The "2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Patients With Atrial Fibrillation" provides recommendations to guide clinicians in the treatment of patients with atrial fibrillation | ||
| 520 | |a METHODS: A comprehensive literature search was conducted from May 12, 2022, to November 3, 2022, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. Additional relevant studies, published through November 2022, during the guideline writing process, were also considered by the writing committee and added to the evidence tables, where appropriate | ||
| 520 | |a STRUCTURE: Atrial fibrillation is the most sustained common arrhythmia, and its incidence and prevalence are increasing in the United States and globally. Recommendations from the "2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation" and the "2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation" have been updated with new evidence to guide clinicians. In addition, new recommendations addressing atrial fibrillation and thromboembolic risk assessment, anticoagulation, left atrial appendage occlusion, atrial fibrillation catheter or surgical ablation, and risk factor modification and atrial fibrillation prevention have been developed | ||
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a ACC/AHA Clinical Practice Guidelines | |
| 650 | 4 | |a acute coronary syndrome | |
| 650 | 4 | |a alcohol | |
| 650 | 4 | |a anticoagulants | |
| 650 | 4 | |a anticoagulation agents | |
| 650 | 4 | |a antiplatelet agents | |
| 650 | 4 | |a apixaban | |
| 650 | 4 | |a atrial fibrillation | |
| 650 | 4 | |a atrial flutter | |
| 650 | 4 | |a cardioversion | |
| 650 | 4 | |a catheter ablation | |
| 650 | 4 | |a coronary artery disease | |
| 650 | 4 | |a coronary heart disease | |
| 650 | 4 | |a dabigatran | |
| 650 | 4 | |a edoxaban | |
| 650 | 4 | |a exercise | |
| 650 | 4 | |a heart failure | |
| 650 | 4 | |a hypertension | |
| 650 | 4 | |a idarucizumab | |
| 650 | 4 | |a left atrial appendage occlusion | |
| 650 | 4 | |a myocardial infarction | |
| 650 | 4 | |a obesity | |
| 650 | 4 | |a percutaneous coronary intervention | |
| 650 | 4 | |a pulmonary vein isolation | |
| 650 | 4 | |a risk factors | |
| 650 | 4 | |a rivaroxaban | |
| 650 | 4 | |a sleep apnea | |
| 650 | 4 | |a stents | |
| 650 | 4 | |a stroke | |
| 650 | 4 | |a surgical ablation | |
| 650 | 4 | |a thromboembolism | |
| 650 | 4 | |a warfarin | |
| 700 | 1 | |a Joglar, José A |e verfasserin |4 aut | |
| 700 | 1 | |a Chung, Mina K |e verfasserin |4 aut | |
| 700 | 1 | |a Armbruster, Anastasia L |e verfasserin |4 aut | |
| 700 | 1 | |a Benjamin, Emelia J |e verfasserin |4 aut | |
| 700 | 1 | |a Chyou, Janice Y |e verfasserin |4 aut | |
| 700 | 1 | |a Cronin, Edmond M |e verfasserin |4 aut | |
| 700 | 1 | |a Deswal, Anita |e verfasserin |4 aut | |
| 700 | 1 | |a Eckhardt, Lee L |e verfasserin |4 aut | |
| 700 | 1 | |a Goldberger, Zachary D |e verfasserin |4 aut | |
| 700 | 1 | |a Gopinathannair, Rakesh |e verfasserin |4 aut | |
| 700 | 1 | |a Gorenek, Bulent |e verfasserin |4 aut | |
| 700 | 1 | |a Hess, Paul L |e verfasserin |4 aut | |
| 700 | 1 | |a Hlatky, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Hogan, Gail |e verfasserin |4 aut | |
| 700 | 1 | |a Ibeh, Chinwe |e verfasserin |4 aut | |
| 700 | 1 | |a Indik, Julia H |e verfasserin |4 aut | |
| 700 | 1 | |a Kido, Kazuhiko |e verfasserin |4 aut | |
| 700 | 1 | |a Kusumoto, Fred |e verfasserin |4 aut | |
| 700 | 1 | |a Link, Mark S |e verfasserin |4 aut | |
| 700 | 1 | |a Linta, Kathleen T |e verfasserin |4 aut | |
| 700 | 1 | |a Marcus, Gregory M |e verfasserin |4 aut | |
| 700 | 1 | |a McCarthy, Patrick M |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Nimesh |e verfasserin |4 aut | |
| 700 | 1 | |a Patton, Kristen K |e verfasserin |4 aut | |
| 700 | 1 | |a Perez, Marco V |e verfasserin |4 aut | |
| 700 | 1 | |a Piccini, Jonathan P |e verfasserin |4 aut | |
| 700 | 1 | |a Russo, Andrea M |e verfasserin |4 aut | |
| 700 | 1 | |a Sanders, Prashanthan |e verfasserin |4 aut | |
| 700 | 1 | |a Streur, Megan M |e verfasserin |4 aut | |
| 700 | 1 | |a Thomas, Kevin L |e verfasserin |4 aut | |
| 700 | 1 | |a Times, Sabrina |e verfasserin |4 aut | |
| 700 | 1 | |a Tisdale, James E |e verfasserin |4 aut | |
| 700 | 1 | |a Valente, Anne Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Van Wagoner, David R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the American College of Cardiology |d 1987 |g 83(2024), 1 vom: 02. Jan., Seite 109-279 |w (DE-627)NLM012608602 |x 1558-3597 |7 nnns |
| 773 | 1 | 8 | |g volume:83 |g year:2024 |g number:1 |g day:02 |g month:01 |g pages:109-279 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jacc.2023.08.017 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 83 |j 2024 |e 1 |b 02 |c 01 |h 109-279 | ||